Literature DB >> 9430189

Update of the NCCN guidelines for treatment of prostate cancer.

R Millikan1, C Logothetis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9430189

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  6 in total

1.  Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer.

Authors:  Nihal E Mohamed; Dana H Bovbjerg; Guy H Montgomery; Simon J Hall; Michael A Diefenbach
Journal:  Urol Oncol       Date:  2011-07-27       Impact factor: 3.498

2.  The diffusion of docetaxel in patients with metastatic prostate cancer.

Authors:  Joseph M Unger; Dawn L Hershman; Diane Martin; Ruth B Etzioni; William E Barlow; Michael LeBlanc; Scott R Ramsey
Journal:  J Natl Cancer Inst       Date:  2014-12-24       Impact factor: 13.506

3.  Estimates and projections of value of life lost from cancer deaths in the United States.

Authors:  K Robin Yabroff; Cathy J Bradley; Angela B Mariotto; Martin L Brown; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2008-12-09       Impact factor: 13.506

4.  Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Authors:  Jason S Kirk; Kevin Schaarschuch; Zafardjan Dalimov; Elena Lasorsa; ShengYu Ku; Swathi Ramakrishnan; Qiang Hu; Gissou Azabdaftari; Jianmin Wang; Roberto Pili; Leigh Ellis
Journal:  Oncotarget       Date:  2015-02-20

Review 5.  Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.

Authors:  Rajni Sethi; Nicholas Sanfilippo
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

6.  A multimedia interactive education system for prostate cancer patients: development and preliminary evaluation.

Authors:  Michael A Diefenbach; Brian P Butz
Journal:  J Med Internet Res       Date:  2004-01-21       Impact factor: 5.428
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.